Bevacizumab-related osteonecrosis of the mandible is a self-limiting disease process

BMJ Case Reports

Volumn , Issue , 2012, Pages

  Bettini, Giordana ^a   Blandamura, Stella ^b   Saia, Giorgia ^a   Bedogni, Alberto ^c  

^a UNIVERSITY OF PADOVA   (Italy)

^b Institute of Pathology   (Italy)

^c UNIVERSITY HOSPITAL OF VERONA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; BEVACIZUMAB; CISPLATIN; CORTICOSTEROID; ERLOTINIB; GEMCITABINE; LINCOMYCIN; TECHNETIUM 99M;

ADULT; ARTICLE; BONE SCINTISCANNING; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; HALITOSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; JAW OSTEONECROSIS; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MOUTH PAIN; MULTIPLE CYCLE TREATMENT; PERIODONTAL ABSCESS; PERIODONTAL DISEASE; PRIORITY JOURNAL; TOOTH PAIN;

EID: 84872148608     PISSN: None     EISSN: 1757790X     Source Type: Journal    
DOI: 10.1136/bcr-2012-007284     Document Type: Article

References (25)

1. Oxnard GR. Bevacizumab for non-small-cell lung cancer. N Engl J Med 2007;356:1373-75.
2. Shih T, Lindley C. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther 2006;28:1779-802.
3. Aragon-Ching JB, Ning YM, Chen CC, et al. Higher incidence of osteonecrosis of the jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents. Cancer Invest 2009;27:221-6.
4. Christodoulou C, Pervena A, Klouvas G, et al. Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone. Oncology 2009;76:209-11.
5. Guarnieri V, Miles D, Nicholas R, et al. Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. Breast Cancer Res Treat 2010;122:181-8.
6. Estilo CL, Fornier M, Farooki A, et al. Osteonecrosis of the jaw related to bevacizumab. J Clin Oncol 2008;26:4037-8.
7. Greuter S, Schmid F, Ruhstaller T, et al. Bevacizumab-associated osteonecrosis of the jaw. Ann Oncol 2008;19:2091-2.
8. Serra F, Paolantonio M, Spoto G, et al. Bevacizumab-related osteonecrosis of the jaw. Int J Immunopathol Parmacol 2009;22:1121-3.
9. Dişel U, Beşen AA, Özylkan Ö, et al. A case report of bevacizumab-related osteonecrosis of the jaw: old problem, new culprit. Oral Oncol 2012;48:2-3.
10. Hopp RN, Pucci J, Santos-Silva AR, et al. Osteonecrosis after administration of intravitreous bevacizumab. J Oral Maxillofac Surg 2012;70:632-5.
11. Badros A, Weikel D, Salama A, et al. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol 2006;24:945-52.
12. Ruggiero SL, Dodson TB, Assael LA, et al. American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws-2009 update. J Oral Maxillofac Surg 2009;67:2-12.
13. Lazarovici TS, Yahalom R, Taicher S, et al. Bisphosphonate-related osteonecrosis of the jaws: a single-center study of 101 patients. J Oral Maxillofac Surg 2009;67:850-5.
14. Ferrara N, Hillan KJ, Novotny W. Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 2005;333:328-35.
15. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005;23:1011-27.
16. Renk M, Crino' L. Advances in anti-VEGF and anti-EGFR therapy for advanced non-small cell lung cancer. Lung Cancer 2009;63:1-9.
17. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non small-cell lung cancer. N Engl J Med 2006;355:2542-50.
18. Eskens FA, Sleijfer S. The use of bevacizumab in colorectal, ling, breast, renal and ovarian cancer: where does it fit? Eur J Cancer 2008;44:2350-6.
19. Gordon CR, Rojavin Y, Patel M, et al. A review on bevacizumab and surgical wound healing. An important warning to all surgeons. Ann Plast Surg 2009;62:707-9.
20. Scappaticci FA, Fehrenbacher L, Cartwright T, et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 2005;91:173-80.
21. Peyruchaud O, Serre CM, NicAmhlaoibh R, et al. Angiostatin inhibits bone metastasis formation in nude mice through a direct anti-osteoclastic activity. J Biol Chem 2003;278:45826-32.
22. Aldridge SE, Lennard TWJ, Williams JR, et al. Vascular endothelial growth factor receptors in osteoclast differentiation and function. Biochem Biophys Res Commun 2005;335:793-8.
23. Yang Q, McHugh KP, Patntirapong S, et al. VEGF enhancement of osteoclast survival and bone resorption involves VEGF receptor-2 signaling and β3 - integrin. Matrix Biol 2008;27:589-99.
24. Nakagawa M, Kaneda T, Arakawa T, et al. Vascular endothelial growth factor (VEGF) directly enhances osteoclastic bone resorption and survival of mature osteoclasts. FEBS Lett 2000;473:161-4.
25. Yuan F, Chen Y, Dellian M, et al. Time-dependent vascular regression and permeability changes in established human tumour xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci USA 1996;93:14765-70.